Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Director | May 12, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 10,000 · Balance 10,000 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Ensisheim Partners, LLC | 1,483 |
Reported balance
Holding disclosure · report date 2026-05-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,483 F2: Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Steven C. Quay. The Reporting Person and Dr. Quay share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.
F2: Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Steven C. Quay. The Reporting Person and Dr. Quay share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 14, 2026 20:27 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-224148 · ownership.xml · nonDerivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:05 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-073521 · ownership.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-05-15 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 12 months following May 15, 2025, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued on May 15, 2025 with an exercise price of $0.99, representing the closing stock price on May 15, 2025. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:00 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000950170-24-079561 · ownership.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-06-27 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 12 months following June 27, 2024, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024 with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024. Read SEC document |
| May 04, 2023 Filed May 5, 2023 23:35 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001437749-23-012869 · rdgdoc.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-04 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. The options were issued at approximately 9:50 a.m. (ET) on May 4, 2023, with an exercise price of $0.662, representing the most recently reported closing stock price on May 3, 2023. Read SEC document |
| May 13, 2022 Filed May 16, 2022 22:24 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001437749-22-012713 · rdgdoc.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-13 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:30 a.m. (ET) on May 13, 2022, with an exercise price of $0.93, representing the most recently reported closing stock price on May 12, 2022. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:18 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001437749-21-012677 · rdgdoc.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| May 15, 2020 Filed May 19, 2020 18:05 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001437749-20-011262 · rdgdoc.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 15, 2020 with an exercise price of $1.70, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| May 17, 2019 Filed May 22, 2019 00:07 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001437749-19-010644 · rdgdoc.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:00 a.m. (ET) on May 17, 2019 with an exercise price of $2.52, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:02 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001615774-18-005996 · s111130_form4.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Read SEC document |
| May 30, 2018 Filed May 31, 2018 19:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseWarrants · Derivative | 2,272 | $1,000.00 Strike: $4.05 | $2,272,000.00 |
DisclosureSEC source: 0001615774-18-004659 · s110547_form4.xml · derivative · entry 2 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,272 Underlying: Common Stock · 2,272 shares Expires 2022-05-30 F4 · price: Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants. F5 · ownership.nature: Securities are owned by Ensisheim Partners, LLC ("Ensisheim"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity. Read SEC document |
| May 30, 2018 Filed May 31, 2018 19:29 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseSeries B Convertible Preferred Stock · Derivative | 8 | $1,000.00 Strike: $3.52 | $8,000.00 |
DisclosureSEC source: 0001615774-18-004659 · s110547_form4.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8 Underlying: Common Stock · 2,273 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $3.52. F4 · price: Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants. F2 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock do not expire. F3 · derivative.underlying_shares: No fractional shares will be issued upon conversion. At its election, the Company will either issue a cash adjustment or round up to the next whole share. The number reflected here assumes rounding up to the next whole share. F5 · ownership.nature: Securities are owned by Ensisheim Partners, LLC ("Ensisheim"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity. Read SEC document |
| May 24, 2017 Filed May 26, 2017 17:41 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 60,202 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001615774-17-002737 · s106360_form4.xml · derivative · entry 1 Chen Shu-Chih · CIK 0001552127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,404 Underlying: Common Stock · 60,202 shares Expires 2027-05-24 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.